|Bid||473.08 x 1000|
|Ask||475.69 x 1100|
|Day's range||471.50 - 480.26|
|52-week range||441.00 - 664.64|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||15.57|
|Earnings date||06 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||647.96|
Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend that REGEN-COV™ (casirivimab with imdevimab) be used in non-hospitalized COVID-19 patients ("outpatients") at high risk of clinical progression. The Category 'AIIa' is a 'strong' rating based on results of randomized trials.
Tejaswini Mishra, PhD, Research Scientist in the Department of Genetics at Stanford University School of Medicine, joins Yahoo Finance’s Alexis Christoforous to discuss the use of wearables to detect COVID-19.